Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies. - Test2 - elhamkhani - TriplyDB

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

http://www.wikidata.org/entity/Q34102657

about

Charge variants in IgG1: Isolation, characterization, in vitro binding properties and pharmacokinetics in rats Functional reconstitution of human FcRn in Madin-Darby canine kidney cells requires co-expressed human beta 2-microglobulin Neonatal Fc receptor mediates internalization of Fc in transfected human endothelial cells Fc-fusion proteins and FcRn: structural insights for longer-lasting and more effective therapeutics The Role of FcRn in Antigen Presentation Unraveling the Interaction between FcRn and Albumin: Opportunities for Design of Albumin-Based Therapeutics A neutralizing anti-gH/gL monoclonal antibody is protective in the guinea pig model of congenital CMV infection X-ray Crystal Structures of Monomeric and Dimeric Peptide Inhibitors in Complex with the Human Neonatal Fc Receptor, FcRn Engineering a Monomeric Fc Domain Modality by N-Glycosylation for the Half-life Extension of Biotherapeutics Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges Targeting FcRn for the modulation of antibody dynamics Neonatal Fc receptor and IgG-based therapeutics The neonatal Fc receptor, FcRn, as a target for drug delivery and therapy Intramuscular delivery of heterodimeric IL-15 DNA in macaques produces systemic levels of bioactive cytokine inducing proliferation of NK and T cells Anti-tumour effects of a specific anti-ADAM17 antibody in an ovarian cancer model in vivo Prevention and treatment of influenza with hyperimmune bovine colostrum antibody Analogies between digital radio and chemical orthogonality as a method for enhanced analysis of molecular recognition events.Enhanced potency of a fucose-free monoclonal antibody being developed as an Ebola virus immunoprotectant.Seizing the strategic opportunities of emerging technologies by building up innovation system: monoclonal antibody development in China.AVX-470: a novel oral anti-TNF antibody with therapeutic potential in inflammatory bowel disease Projecting human pharmacokinetics of monoclonal antibodies from nonclinical data: comparative evaluation of prediction approaches in early drug development.Impact of SPR biosensor assay configuration on antibody: Neonatal Fc receptor binding data.Single-chain antibody and its derivatives directed against vascular endothelial growth factor: application for antiangiogenic gene therapy.Noise suppression of point spread functions and its influence on deconvolution of three-dimensional fluorescence microscopy image sets.Reduction of IgG in nonhuman primates by a peptide antagonist of the neonatal Fc receptor FcRn.Aglycosylated IgG variants expressed in bacteria that selectively bind FcgammaRI potentiate tumor cell killing by monocyte-dendritic cells.Quantitative cumulative biodistribution of antibodies in mice: effect of modulating binding affinity to the neonatal Fc receptor Extending serum half-life of albumin by engineering neonatal Fc receptor (FcRn) binding.Projecting human pharmacokinetics of therapeutic antibodies from nonclinical data: what have we learned?Targeting FcRn for therapy: from live cell imaging to in vivo studies in mice.High-dose IgG therapy mitigates bile duct-targeted inflammation and obstruction in a mouse model of biliary atresia Role of Homologous Fc Fragment in the Potency and Efficacy of Anti-Botulinum Antibody Preparations Divergent outcomes following transcytosis of IgG targeting intracellular and extracellular chlamydial antigens Tailoring the pharmacokinetics and positron emission tomography imaging properties of anti-carcinoembryonic antigen single-chain Fv-Fc antibody fragments.Combined affinity and rate constant distributions of ligand populations from experimental surface binding kinetics and equilibria.Maternal antibodies: clinical significance, mechanism of interference with immune responses, and possible vaccination strategies.Correlations between pharmacokinetics of IgG antibodies in primates vs. FcRn-transgenic mice reveal a rodent model with predictive capabilities.Neonatal Fc receptor: from immunity to therapeutics Colostrum from cows immunized with a vaccine associated with bovine neonatal pancytopenia contains allo-antibodies that cross-react with human MHC-I molecules Recombinant anthrax toxin receptor-Fc fusion proteins produced in plants protect rabbits against inhalational anthrax.

P2860

Q24619854-D8341EB5-F2A9-4E88-9F65-7146D75F1E64 Q24645189-4B1C2E9D-9930-4449-A114-50C9B9CB769E Q24651849-5A6D1F99-0EC7-4330-91B1-50D7E5C94F52 Q26822421-15A72FC0-419C-4A01-800C-ECB90754E950 Q26852988-0A0D9DB7-4CAD-4D82-BCFF-D4AA316B672F Q27027238-86CCC3B6-03B9-4B81-A0B4-46F928547D31 Q27329077-49E6F7D5-7617-429A-9168-FED274CFFF49 Q27662922-87F79279-DF51-45A6-8190-7637DCF2E5CA Q27677555-B91445BC-B6AC-4973-B2B7-44EF10F93E1F Q28079835-4CF87B5E-D022-46C5-9870-7EC3E84983BA Q28080589-6F92D414-D267-4F0D-A1C8-7267154E0E78 Q28252134-D624A2F7-8DB4-46CE-B78B-02820E1DA914 Q28257521-118D93D0-984A-4D85-B280-4B734473AEA9 Q28652428-C6E9485A-60D1-4195-9670-40B8F4367436 Q28727262-0C391F10-8DE9-4E9D-9B02-00D37590F5FC Q28748705-6A80689C-1935-4379-990D-25739B857DA3 Q28755595-C2AFB8AB-DB84-4AA6-8141-D93E0AAEDD8A Q30224854-0D5A136D-86D6-44F6-8B54-BFECEB945644 Q30387074-D4BEDB59-48F1-472C-B324-2C3E086D4AA0 Q30565359-F4ADE6D7-00C1-43AC-8E17-A9A101EFDF0E Q30930928-44A0620A-8CF9-40F1-B933-1410423660EC Q31150455-61586FAD-FD27-4E82-94B2-A7E4B92304C5 Q31156150-18950DBA-1CB3-4135-8BDF-DF1069CEC15E Q33210971-7658A488-4015-4ED1-89B5-C33EC301B55E Q33319667-4073555D-E0F7-4A27-8356-22D91E51D799 Q33524710-56007245-CE33-4411-88A3-81059CC0173D Q33573587-0488B757-D0D5-458B-B9F5-B8F6761D52D4 Q33676732-166A7C68-8ED5-4611-8328-E1367A6EF32B Q33723852-22BFBB3A-A834-41C6-A57B-F5EDD5A7E108 Q33758483-77AF263D-3E2B-484B-8032-ACD3FD2082A5 Q33774295-E412425C-A2E8-4836-BFDF-8D61E660A010 Q33845127-002F01CC-C3CE-4498-905C-F1DAB9AD1574 Q33870404-241A56BE-5B92-4571-9749-B57917F572C2 Q34134336-C36AEDFC-62CD-4641-A138-2FC904152513 Q34181558-A297ABC0-24FA-4E50-8DE1-0D5CAFEF99E9 Q34193265-640D54A0-B240-4E57-9FC6-B58182FC87F3 Q34212762-AC980EEF-B16F-4E51-A813-95D3B6A9BCD9 Q34268801-9FB9E66C-CEB9-4C8F-86EC-72B98931E417 Q34316801-0ABF179A-35EA-41D6-AC76-D2470856DE40 Q34483688-B28DE9E3-94C5-4948-AE78-4B56827C02B2

P2860

Differences in promiscuity for antibody-FcRn interactions across species: implications for therapeutic antibodies.

http://www.wikidata.org/entity/Q34102657

description

2001 nî lūn-bûn

@nan

2001 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի դեկտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Differences in promiscuity for ...... ns for therapeutic antibodies.

@ast

Differences in promiscuity for ...... ns for therapeutic antibodies.

@en

Differences in promiscuity for ...... ns for therapeutic antibodies.

@nl

type

label

Differences in promiscuity for ...... ns for therapeutic antibodies.

@ast

Differences in promiscuity for ...... ns for therapeutic antibodies.

@en

Differences in promiscuity for ...... ns for therapeutic antibodies.

@nl

prefLabel

Differences in promiscuity for ...... ns for therapeutic antibodies.

@ast

Differences in promiscuity for ...... ns for therapeutic antibodies.

@en

Differences in promiscuity for ...... ns for therapeutic antibodies.

@nl

P1433

Q34102657-60E7F8E2-21C3-43F9-9B27-34AECF19E8A9

P1476

Q34102657-750BFF44-8CF2-4C9B-9430-C41FF919952E

P2093

Q34102657-4B2D639B-B7FE-4825-8433-5D4DC356E532

Q34102657-6C2D50CE-DFE9-4EA4-BA28-A93D0D2217E2

Q34102657-C80BDA47-6F87-4D17-9BD3-6D0CA1C3F900

Q34102657-CAC8BD4D-1629-492A-8D41-362394EF1CF4

P2860

Q34102657-00501C3B-B7B4-45DC-9112-EF02962B286A

Q34102657-021E01D4-516B-445D-A9C9-FB313CEAC780

Q34102657-045C77BE-A793-4504-86D2-C770D7805407

Q34102657-0CE47C1F-D37A-45AC-B50C-22017E3C60A6

Q34102657-1272ADE2-1A12-41C8-9D8D-30224BEAC953

Q34102657-22B33164-781B-4134-AF6F-3D9FD2877EF7

Q34102657-285B7838-5B69-4C77-A5C6-C8EBF32875FB

Q34102657-36715025-44D1-4CFE-BE95-85383397DC06

Q34102657-4ABB21BB-F37B-44A3-9B26-7E0B7621220F

Q34102657-5833095A-3435-4D8B-9C6B-8FAF899A3E61

P304

Q34102657-4B527E2B-DEB5-43AD-8A23-584945B24251

P31

Q34102657-5CA81698-67AF-43D7-ACF5-402078355088

P356

Q34102657-EDC4E929-FB12-4867-8F60-0906948AEF17

P433

Q34102657-4490A17C-67ED-4A96-AE50-DD24FE7EE22E

P478

Q34102657-5D2163F6-E657-4C23-BED2-8C228B8A4498

P577

Q34102657-10BD8CAD-9DBF-4380-B909-9FAC7B80D7EC

P5875

Q34102657-35050B4B-71AE-4D2A-B2F8-F91CF75059D1

P698

Q34102657-CF26BC42-B015-4C8C-B2F2-DBE335AEFB0A

P921

Q34102657-3615EF8D-250B-44B8-A240-F2FD9FE7BD09

P356

P1433

International Immunology

P1476

Differences in promiscuity for ...... ns for therapeutic antibodies.

@en

P2093

Ghetie V

http://www.w3.org/2001/XMLSchema#string

Ober RJ

http://www.w3.org/2001/XMLSchema#string

Radu CG

http://www.w3.org/2001/XMLSchema#string

Ward ES

http://www.w3.org/2001/XMLSchema#string

P2860

A major histocompatibility complex class I-like Fc receptor cloned from human placenta: possible role in transfer of immunoglobulin G from mother to fetus

Crystal structure of the human leukocyte Fc receptor, Fc gammaRIIa

The 3.2-A crystal structure of the human IgG1 Fc fragment-Fc gammaRIII complex

Crystal structure and immunoglobulin G binding properties of the human major histocompatibility complex-related Fc receptor(,)

Crystal structure at 2.8 A of an FcRn/heterodimeric Fc complex: mechanism of pH-dependent binding

Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution

Crystal structure of the complex of rat neonatal Fc receptor with Fc

The MHC class I-related receptor, FcRn, plays an essential role in the maternofetal transfer of gamma-globulin in humans

An Fc receptor structurally related to MHC class I antigens

Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension

P304

1551-1559

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INTIMM/13.12.1551

http://www.w3.org/2001/XMLSchema#string

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P577

2001-12-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

31100158

http://www.w3.org/2001/XMLSchema#string

P698

11717196

http://www.w3.org/2001/XMLSchema#string

P921